Biomarkers - Lectures

Welcome from key members of the four organizing bodies

Epigenetic markers in cancer

Genomics Driven Approaches

Clinical reporting of NGS data

Progress and Implications of Novel Technology for Clinical Trials

Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients

Biology-Driven Clinical Trials

Molecular Profiling based Assignment of Cancer Therapy

Biology-Driven Clinical Trials

Rationale of the Design of the SHIVA trial

Biology-Driven Clinical Trials

Rationale of the Design of the I-SPY trial

Biology-Driven Clinical Trials

Rationale of the Design of the WINTHER Trial

Biology-Driven Clinical Trials

Two-Stage adaptive cutoff design for building and validating a prognostic biomarker signature

New Trial Concepts and Challenges for the Future

Bioinformatics analysis for real-time applications

New Trial Concepts and Challenges for the Future

Biostatistical challenges for the design of biology-driven trials

New Trial Concepts and Challenges for the Future

Circulating Free DNA, Mutation Detection and Predictive Biomarker Potential

Biomarkers for Antitumour Evaluation

Patient Selection Markers for Anti-angiogenic Agents in Metastatic Renal Cell Carcinoma: Dream or Reality?

Proffered Paper Session

Incorporating Biomarkers Into Phase 2 Trials – 5 Multiple Options, Multiple Challenges

Changing Landscape of Clinical Trial Design- Small Studies, Large Differences?